Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
"Masculinity theory" was used to report the impact of having both a BRCA1/2 mutation and PCa.
|
28812325 |
2017 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The risk of prostate cancer is known to be elevated in carriers of germline mutations in BRCA2, and possibly also in carriers of BRCA1 and CHEK2 mutations.
|
15280931 |
2004 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Four microsatellite polymorphic markers (D8S133, D8S136, and D8S137, for a putative tumor suppressor gene on chromosome 8p, and D17S855, for the BRCA1 gene on chromosome 17q) were used to examine the pattern of allelic loss in prostate cancer from 19 patients who had two or more distantly separate tumors (i.e., located on contralateral sides or separated by at least half the anterior-posterior diameter of the prostate).
|
9462681 |
1998 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, recent genomic analysis has revealed that germline or somatic inactivating mutations in BRCA1 or BRCA2, or other genes involved in the homologous recombination (HR) pathway of DNA repair collectively occur in as much as 20%-25% of advanced prostate cancers.
|
27317574 |
2016 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In the present study it was demonstrated that PARP1-siRNA could reduce prostate cancer (PCa) cell progression regardless of the BRCA1/2 mutation.
|
29393407 |
2018 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Early age at diagnosis of breast cancer, ovarian cancer, bilateral breast cancer, concomitant breast/ovarian cancer in a single patient and prostate cancer but not unilateral breast cancer were associated with BRCA1 and BRCA2 mutations.
|
11802208 |
2002 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, the clustering of early pancreatic cancer in families with two breast cancers under age 50 years, the aggregation of ovarian cancer in families with breast and ovarian cancers, and the increased incidence of early onset prostate cancer in families with male breast cancer seem to be due to other effects unrelated to BRCA1/2 mutations.
|
15550590 |
2004 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Blood DNA from affected individuals in 38 prostate cancer clusters was analyzed for germ-line mutations in BRCA1 and BRCA2 to assess the contribution of each of these genes to familial prostate cancer.
|
10969800 |
2000 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To establish whether or not inherited variation in BRCA1 influences prostate cancer risk we genotyped 1793 men with prostate cancer in Poland and 4570 controls for three founder mutations (C61G, 4153delA and 5382insC).
|
18090912 |
2008 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1.
|
14601029 |
2003 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The FDA authorized 23andMe to market the first direct-to-consumer test to check for three BRCA1/2 mutations associated with a higher risk of developing breast, ovarian, and prostate cancers.
|
29540360 |
2018 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PCa with germline BRCA1/2 mutations were more frequently associated with Gleason ≥ 8 (P = .00003), T3/T4 stage (P = .003), nodal involvement (P = .00005), and metastases at diagnosis (P = .005) than PCa in noncarriers.
|
23569316 |
2013 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.
|
18182994 |
2008 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Several studies have provided evidence that germline mutations in BRCA1 and BRCA2 confer an increased risk of prostate cancer.
|
10344217 |
1999 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
For example, prostate cancer risk by age 80 years at the 5th and 95th percentiles of the PRS varies from 7% to 26% for carriers of BRCA1 mutations and from 19% to 61% for carriers of BRCA2 mutations, respectively.
|
28448241 |
2017 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Prior data suggests that men carrying mutations in the BRCA1& 2 genes may be at increased risk of developing prostate cancer.
|
25047061 |
2014 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline breast cancer 1 gene (BRCA1) and breast cancer 2 gene (BRCA2) mutations are implicated in the highest risk of prostate cancer (PC) predisposition and aggressiveness.
|
28280302 |
2017 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In addition, the reason that BRCA1 mutation carriers develop specific tumor types (breast and ovarian cancers in women and possibly prostate cancers in men) is not clearly understood.
|
12767038 |
2003 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 gene mutations may also be related with other types of cancers such as prostate cancer and colorectal cancer.
|
10810408 |
2000 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To better understand the correlation between BRCA1/2 mutations and the immune phenotype in prostate cancer, we characterized the immune infiltrate of eight BRCA2-mutated tumors in comparison with eight BRCA1/2 wild-type patients by T-cell receptor sequencing and immunohistochemistry for CD45, CD4, CD8, FOXP3, and CD163.
|
31549213 |
2019 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We tested for the BRCA1 185delAG frameshift mutation, found in 0.9% of Ashkenazi Jews, and the BRCA2 6174delT mutation, found in 1% of Ashkenazi Jews, in Ashkenazi Jewish men with prostate cancer.
|
9743298 |
1998 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study shows that elevated expression of Ki-67 is associated both with aggressive prostate cancers and with high Gleason score irrespective of whether their occurrence is against a background of BRCA1 or BRCA2 mutations or as sporadic disease.
|
20043088 |
2010 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Men with BRCA1 or BRCA2 mutations were more likely to have a family history of prostate cancer (P = 0.025).
|
17592676 |
2007 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Prostate cancer risk was increased (OR, 1.9; 95% CI 0.9-4.1) for BRCA2 mutation carriers but not for BRCA1 mutation carriers.
|
19188187 |
2009 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Of 3607 men (mean [SD] age at testing, 67 [9.51] years; mean age at diagnosis, 60 [9.05] years) with a personal diagnosis of prostate cancer who were referred for genetic testing, 620 (17.2%) had positive germline variants, of which only 30.7% were variants in BRCA1/2.
|
30730552 |
2019 |